explore -WSS

explore

author：entertainment 2025-09-28 22:28:26 - browse：3535

NEW ORLEANS — For some patients suffering with certain blood cancers, CAR-T therapy can offer the tantalizing chance to end their disease with a single treatment.

But the immunotherapy takes time to manufacture, and patients often have to wait weeks to actually receive an infusion once they’re eligible. For some patients with especially aggressive cancer, they can die while waiting for the therapy to arrive.

That’s spurred CAR-T manufacturers to find ways to speed up manufacturing. The industry is testing newer — and possibly better — CAR-T cells that can be made more quickly. Researchers working with Novartis presented Phase 1 clinical trial data Sunday on a new CAR-T cell made with a rapid manufacturing process at the annual American Society of Hematology meeting.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Bristol Myers buys into radiopharmaceuticals with RayzeBio

WSS

In Spain, a hospital brews its own CAR

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

The haunting brain science of long Covid

What causes rare myocarditis in young men after Covid vaccines?

Why health records don't always know when patients are dead

Device maker Teleflex to acquire urology company for $600M

hotspot

explore

Wikipedia

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

David Ricks of Eli Lilly: best biopharma CEO of 2023

FDA approval of Sarepta Duchenne genetic therapy gives me hope

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

Drug repurposing or repositioning? The language matters

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Drug repurposing or repositioning? The language matters

Bronny James, LeBron's son, suffers cardiac arrest during basketball practice at USC

Anesthesiologist group: stop taking Ozempic before surgery

Albert Bourla of Pfizer: worst biopharma CEO of 2023

knowledge

A new crop of companies is reshaping the health data economy

UHS says company favors patients whose insurance pays more

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

What to watch for from Zogenix and Amicus clinical trials

Biogen says it will cut costs by $700 million, slash 1,000 jobs

leisure time

hotspot

hotspot

focus